CAJ | 학술논문

目的探讨肿瘤转移抑制基因-1(TMSG-1,亦称LASS2)在人不同转移潜能前列腺癌细胞株中与前列腺癌组织中的表达及其临床意义.方法采用实时荧光定量聚合酶链反应(PCR)及细胞爬片免疫荧光组织化学方法,检测TMSG-1在人不同转移潜能前列腺癌细胞株低转移潜能(PC-3M-2134)和高转移潜能(PC-3M-IE8)中的表达.并采用免疫组织化学方法检测TMSG-1在人前列腺增生及前列腺癌组织中的表达,同时探讨其与临床病理特征之间的关系.结果 TMSG-1在PC-3M-284细胞株中的mRNA及蛋白表达(2.70±0.30、75.26±2.68)均明显高于在PC-3M-IE8细胞株中的表达(1.10±0.20、38.08±1.84),差异有统计学意义(P＜0.05).通过免疫组织化学观察表明TMSG-1在前列腺增生及前列腺癌组织中均有表达,但在前列腺增生中的阳性表达率(32/40)明显高于在前列腺癌中的阳性表达率(21/60).两者差异有统计学意义(P＜0.05).并且TMSG-1在前列腺癌组织中的表达与年龄、Gleason分级、淋巴结转移及TNM分期密切相关(P＜0.05),而与肿瘤的大小无明显相关.结论 TMSG-1在低转移潜能前列腺癌细胞株中的mRNA及蛋白表达明显高于在高转移潜能前列腺癌细胞株中的表达,证明它是一种肿瘤转移抑制基因.TMSG-1在人前列腺增生与前列腺癌组织中的表达之间差异有统计学意义,并且TMSG-1在前列腺癌中的表达与年龄、Gleason分级、淋巴结转移及TNM分期密切相关.
목적 탐토종류전이억제기인-1(TMSG-1,역칭LASS2)재인불동전이잠능전렬선암세포주중여전렬선암조직중적표체급기림상의의.방법 채용실시형광정량취합매련반응(PCR)급세포파편면역형광조직화학방법,검측TMSG-1재인불동전이잠능전렬선암세포주저전이잠능(PC-3M-2134)화고전이잠능(PC-3M-IE8)중적표체.병채용면역조직화학방법검측TMSG-1재인전렬선증생급전렬선암조직중적표체,동시탐토기여림상병리특정지간적관계.결과 TMSG-1재PC-3M-284세포주중적mRNA급단백표체(2.70±0.30、75.26±2.68)균명현고우재PC-3M-IE8세포주중적표체(1.10±0.20、38.08±1.84),차이유통계학의의(P＜0.05).통과면역조직화학관찰표명TMSG-1재전렬선증생급전렬선암조직중균유표체,단재전렬선증생중적양성표체솔(32/40)명현고우재전렬선암중적양성표체솔(21/60).량자차이유통계학의의(P＜0.05).병차TMSG-1재전렬선암조직중적표체여년령、Gleason분급、림파결전이급TNM분기밀절상관(P＜0.05),이여종류적대소무명현상관.결론 TMSG-1재저전이잠능전렬선암세포주중적mRNA급단백표체명현고우재고전이잠능전렬선암세포주중적표체,증명타시일충종류전이억제기인.TMSG-1재인전렬선증생여전렬선암조직중적표체지간차이유통계학의의,병차TMSG-1재전렬선암중적표체여년령、Gleason분급、림파결전이급TNM분기밀절상관.
Objective To investigate the expression of tumor metastasis suppressor gene 1 (TMSG-1 as well LASS2) in different prostate cancer cell lines and prostate cancer tissues and its clinical significance. Methods Sixty patients with prostate cancer had undergone surgery between 2008 and 2010.Forty patients with prostatic hyperplasia were chosen. Immunofluorescence histochemistry was used to study the distribution of TMSG-1 in cells, immunohistochemistry was used to observe the difference in TMSG-1 expression between prostatic hyperplasia and prostate cancer tissues, and the relationship between the TMSG-1 expression and clinicopathological features in prostate cancer tissues was analyzed. Results The level of TMSG-1 mRNA in PC-3M-2B4 cell line with low metastatic potentiality (2. 70 ±0. 30) was higher than in PC-3M-IE8 cell line (1. 10 ±0. 20). Immunofluorescence histochemistry revealed that most of the collected prostate cancers and prostatic hyperplasia tissues expressed TMSG-1 in cytoplasma, and nuclei were stained in a few of prostate cancer tissues. The average fluorescence intensity of TMSG-1 in PC-3M-2B4 cells (75. 26 ±2. 68) was obviously higher than in PC-3M-IE8 cells (38. 08 ± 1. 84). There was obviously different expression of TMSG-1 between prostate cancers (21/60) and prostatic hyperplasia ( 32/40 ) ( P ＜0. 05 ) . The TMSG-1 levels in prostate cancer tissue were significantly correlated with ages,Gleason grade, lymph node metastasis and tumor, nodes, metastasis (TNM) staging (P ＜0. 05) , but not with the size of tumor. Conclusion The expression level of TMSG-1 mRNA and protein in prostate cancer cell lines with low metastatic potentials significantly higher than in prostate carcinoma cell lines with high metastatic potentials, which proves that TMSG-1 is a tumor metastasis suppressor gene. From the difference in the TMSG-1 expression between human prostatic hyperplasia and prostate cancer tissues and the correlation with age, Gleason grade, lymph node metastasis and TNM stage in prostate cancers, we infer that TMSG-1 is an important prognostic indicator in judging prostate cancer cell growth, progression and metastasis.